Cargando…

Dose Escalation of Oropharyngeal Cancer: Long-Time Follow-Up and Side Effects

SIMPLE SUMMARY: In head and neck cancer, local recurrences are unfortunately common. A more intense local treatment, such as an increased radiation dose to the primary tumour, could potentially prevent some of these recurrencies. Previous studies have not shown an increased risk of side effects with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Embring, Anna, Onjukka, Eva, Mercke, Claes, Lax, Ingmar, Berglund, Anders, Friesland, Signe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177133/ https://www.ncbi.nlm.nih.gov/pubmed/37174046 http://dx.doi.org/10.3390/cancers15092580

Ejemplares similares

Dose escalation in oropharyngeal cancer: a comparison of simultaneous integrated boost and brachytherapy boost
por: Embring, Anna, et al.
Publicado: (2023)

Re-Irradiation for Head and Neck Cancer: Cumulative Dose to Organs at Risk and Late Side Effects
por: Embring, Anna, et al.
Publicado: (2021)

Overlapping volumes in re-irradiation for head and neck cancer – an important factor for patient selection
por: Embring, Anna, et al.
Publicado: (2020)

Modeling of Xerostomia After Radiotherapy for Head and Neck Cancer: A Registry Study
por: Onjukka, Eva, et al.
Publicado: (2020)

Radiotherapy—Dose Escalated for Large Volume Primary Tumors—And Cetuximab with or without Induction Chemotherapy for HPV Associated Squamous Cell Carcinoma of the Head and Neck—A Randomized Phase II Trial
por: Mercke, Claes, et al.
Publicado: (2023)

Long-Term Survival and Recurrence in Oropharyngeal Squamous Cell Carcinoma in Relation to Subsites, HPV, and p16-Status
por: Wendt, Malin, et al.
Publicado: (2021)

A retrospective study of SBRT of metastases in patients with primary sarcoma
por: Stragliotto, Christina Linder, et al.
Publicado: (2012)

Adenoid Cystic Carcinoma (AdCC): A Clinical Survey of a Large Patient Cohort
por: Zupancic, Mark, et al.
Publicado: (2023)

Adaptive dose escalated radiotherapy in oropharyngeal cancers: a treatment planning feasibility study
por: Grocutt, Laura, et al.
Publicado: (2022)

Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up
por: Creak, A, et al.
Publicado: (2013)

Phase I trial of dose-escalated stereotactic radiosurgery (SRS) boost for unfavorable locally advanced oropharyngeal cancer
por: Vempati, Prashant, et al.
Publicado: (2020)

The rationale for HPV-related oropharyngeal cancer de-escalation treatment strategies
por: Wierzbicka, Małgorzata, et al.
Publicado: (2015)

Survey of radiation field and dose in human papillomavirus-positive oropharyngeal cancer: is de-escalation actually applied in clinical practice?
por: Choi, Kyu Hye, et al.
Publicado: (2021)

De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation
por: Thomas, Pepijn W. A., et al.
Publicado: (2022)

A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes
por: Maity, Amit, et al.
Publicado: (2021)

Toxicity of dose-escalated radiotherapy up to 84 Gy for prostate cancer
por: Rosenbrock, Johannes, et al.
Publicado: (2023)

Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?
por: Mirghani, Haitham, et al.
Publicado: (2017)

Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohn’s Disease during One-Year Follow-Up
por: Bendix, Mia, et al.
Publicado: (2021)

An Outbreak of Oropharyngeal Tularemia with Cervical Adenopathy Predominantly in the Left Side
por: Sencan, Irfan, et al.
Publicado: (2009)

De-Escalation Strategies for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma—Where Are We Now?
por: Silver, Jennifer A., et al.
Publicado: (2022)

De-escalated radiation for human papillomavirus virus-related oropharyngeal cancer: evolving paradigms and future strategies
por: Chen, Allen M.
Publicado: (2023)

Relationships Between Frequency of Moderate Physical Activity and Longevity: An 11-Year Follow-up Study
por: Rennemark, Mikael, et al.
Publicado: (2018)

Radiation dose escalation based on FDG-PET driven dose painting by numbers in oropharyngeal squamous cell carcinoma: a dosimetric comparison between TomoTherapy-HA and RapidArc
por: Differding, Sarah, et al.
Publicado: (2017)

Dose escalation of a curcuminoid formulation
por: Lao, Christopher D, et al.
Publicado: (2006)

Long-Term Outcomes of Dose-Escalated Hypofractionated Radiotherapy in Localized Prostate Cancer
por: Lazo, Antonio, et al.
Publicado: (2022)

Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects
por: Dearnaley, D P, et al.
Publicado: (2005)

Clinical Outcomes Following Dose-Escalated Proton Therapy for Skull-Base Chordoma
por: Holtzman, Adam L., et al.
Publicado: (2021)

De-escalation of radiation dose for human papillomavirus-positive oropharyngeal head and neck squamous cell carcinoma: A case report and preclinical and clinical literature review
por: WU, CHENG-CHIA, et al.
Publicado: (2016)

Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease
por: Lenders, Malte, et al.
Publicado: (2022)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer
por: Erselcan, T, et al.
Publicado: (2000)

Compromised quality of life in adult patients who have received a radiation dose towards the basal part of the brain. A case-control study in long-term survivors from cancer in the head and neck region
por: Löfdahl, Elisabet, et al.
Publicado: (2012)

What is the future of treatment de-escalation for HPV-positive oropharyngeal cancer? A review of ongoing clinical trials
por: Mensour, Emma A., et al.
Publicado: (2022)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors
por: Yao, James C, et al.
Publicado: (2017)

Radiation treatment planning with embedded dose escalation
por: Hrinivich, William T., et al.
Publicado: (2019)

The role of biological dose-escalation for pancreatic cancer
por: Bruynzeel, Anna M.E., et al.
Publicado: (2019)

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
por: Elganainy, Dalia, et al.
Publicado: (2018)

National trends in radiation dose escalation for glioblastoma
por: Wegner, Rodney E., et al.
Publicado: (2019)

Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_56r737s5v8ci3tfoq3tiu5m7o8